Moffitt Cancer Center Partners with Cryoport to Enhance Cancer Research Facilities

Moffitt Cancer Center Partners with Cryoport to Innovate Cancer Research

Moffitt Cancer Center, a prominent institution designated by the National Cancer Institute, has announced a groundbreaking strategic partnership with Cryoport, Inc., a global leader in supply chain solutions for the life sciences sector. This collaboration aims to enhance the biorepository services at Moffitt's burgeoning Speros campus in Pasco County, Florida. Cryoport’s advanced biorepository unit, CRYOGENE, will play a crucial role in the storage and management of biological specimens, ultimately accelerating the development of innovative therapies for cancer patients.

Patrick Hwu, M.D., Moffitt’s president and CEO, expressed his vision of transforming Speros into the global center for cell and gene therapy. With the integration of CRYOGENE's top-notch facilities into the Speros campus, Moffitt aims to foster rapid scientific advancements and collaborative partnerships focused on developing new therapies that can save lives more efficiently.

Marshall Griswold, CEO of CRYOGENE, emphasized the synergy that this location brings to biotech and research companies. Having CRYOGENE’s expertise and facility accessible right on Moffitt's research campus will provide essential tools and resources for enhancing research capabilities, aiming to improve patient outcomes collectively.

The establishment of CRYOGENE's state-of-the-art biostorage facility is a pivotal element of Moffitt's transformation plan for its Speros campus, which will become a hub for cutting-edge treatments, including cell and gene therapies, immunotherapies, and advanced radiation treatments. This initial phase surrounds Moffitt's expansive 250,000-square-foot Discovery Innovation Center dedicated to research.

Jerrell Shelton, Cryoport's CEO, highlighted the partnership's commitment to patient care and medical research. The collaboration will bring innovative biostorage and logistical services that will pave the way for accelerated scientific breakthroughs in cancer treatments, underscoring their shared mission to enhance patient lives.

Biorepositories play a critical role in the evolution of cell and gene therapies, an industry expected to surpass $97 billion by 2033, with an impressive growth rate of 18.3% annually from 2024 to 2033. CRYOGENE employs optimized storage solutions and rigorous quality controls to ensure reliable production and preservation of biological materials, boosting the efficiency of adoptive cell therapies.

Moffitt's collaboration with Cryoport will also augment its existing health systems as it addresses rising demands in blood sciences and biobanking protocols. The new biorepository will enable streamlined access to crucial research and clinical activities, while providing logistical support for distributing research materials.

Sabi Singh, Moffitt's Chief Operating Officer, articulated that integrating Cryoport’s industry-leading biorepository is foundational to Speros’ mission. Speros is designed to serve as a catalyst for transformative science that positively impacts human health.

Moffitt's development vision for the Speros campus includes multiple phases focusing on pivotal activities such as cell and gene therapies, artificial intelligence, and biotechnology, alongside supporting infrastructural expansion like health care and basic research amenities. Construction on Moffitt’s outpatient and proton therapy center is already underway, with completion anticipated by 2026.

Cryoport, recognized for its exceptional biostorage solutions and management of over 25 million samples, boasts facilities in Houston and San Antonio, Texas, offering premier services in biostorage for the research, biotech, and pharmaceutical sectors.

Speros FL aims to synergize various scientific and health care disciplines to address complex challenges and enhance human life. This initiative focuses on progressive sectors, such as biotechnology and artificial intelligence, while stimulating growth within the local and international health care landscapes.

For more information about Moffitt Cancer Center, please visit MOFFITT.org. To learn more about Cryoport’s capabilities and innovations, explore Cryoport Inc.'s website.